▼ -6.22% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for ShockWave Medical in the last 3 months. The average price target is $109.50, with a high forecast of $134.00 and a low forecast of $23.00. The average price target represents a -6.22% upside from the last price of $116.76.
The current consensus among 6 polled investment analysts is to hold stock in ShockWave Medical. This rating has held steady since January 2020, when it changed from a Buy consensus rating.
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.